• 1
    Wood JM, Schild GC, Newman RW, Seagroatt V. An improved single-radial-immunodiffusion technique for the assay of influenza haemagglutinin antigen: application for potency determinations of inactivated whole virus and subunit vaccines. J Biol Stand 1977; 5:237247.
  • 2
    Williams MS. Single-radial-immunodiffusion as an in vitro potency assay for human inactivated viral vaccines. Vet Microbiol 1993; 37:253262.
  • 3
    Minor PD, Engelhardt OG, Wood JM et al. Current challenges in implementing cell-derived influenza vaccines: implications for production and regulation, July 2007, NIBSC, Potters Bar, UK. Vaccine 2009; 27:29072913.
  • 4
    Cate TR, Couch RB, Parker D, Baxter B. Reactogenicity, immunogenicity, and antibody persistence in adults given inactivated influenza virus vaccines – 1978. Rev Infect Dis 1983; 5:737747.
  • 5
    La Montagne JR, Noble GR, Quinnan GV et al. Summary of clinical trials of inactivated influenza vaccine – 1978. Rev Infect Dis 1983; 5:723736.
  • 6
    Quinnan GV, Schooley R, Dolin R, Ennis FA, Gross P, Gwaltney JM. Serologic responses and systemic reactions in adults after vaccination with monovalent A/USSR/77 and trivalent A/USSR/77, A/Texas/77, B/Hong Kong/72 influenza vaccines. Rev Infect Dis 1983; 5:748757.
  • 7
    Wright PF, Cherry JD, Foy HM et al. Antigenicity and reactogenicity of influenza A/USSR/77 virus vaccine in children–a multicentered evaluation of dosage and safety. Rev Infect Dis 1983; 5:758764.
  • 8
    Hobson D, Curry RL, Beare AS, Ward-Gardner A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (Lond) 1972; 70:767777.
  • 9
    Hardy S, Eichelberger M, Griffiths E, Weir JP, Wood D, Alfonso C. Confronting the next pandemic–workshop on lessons learned from potency testing of pandemic (H1N1) 2009 influenza vaccines and considerations for future potency tests, Ottawa, Canada, July 27–29, 2010. Influenza Other Respir Viruses 2011; 5:438442.
  • 10
    Kapteyn JC, Porre AM, de Rond EJ et al. HPLC-based quantification of haemagglutinin in the production of egg- and MDCK cell-derived influenza virus seasonal and pandemic vaccines. Vaccine 2009; 27:14681477.
  • 11
    Garcia-Canas V, Lorbetskie B, Bertrand D, Cyr TD, Girard M. Selective and quantitative detection of influenza virus proteins in commercial vaccines using two-dimensional high-performance liquid chromatography and fluorescence detection. Anal Chem 2007; 79:31643172.
  • 12
    Williams TL, Pirkle JL, Barr JR. Simultaneous quantification of hemagglutinin and neuraminidase of influenza virus using isotope dilution mass spectrometry. Vaccine 2012; 30:24752482.
  • 13
    Williams TL, Luna L, Guo Z et al. Quantification of influenza virus hemagglutinins in complex mixtures using isotope dilution tandem mass spectrometry. Vaccine 2008; 26:25102520.
  • 14
    Getie-Kebtie M, Chen D, Eichelberger M, Alterman M. Proteomics-based characterization of hemagglutinins in different strains of influenza virus. Proteomics Clin Appl 2009; 3:979988.
  • 15
    Creskey MC, Li C, Wang J et al. Simultaneous quantification of the viral antigens hemagglutinin and neuraminidase in influenza vaccines by LC-MSE. Vaccine 2012; 30:47624770.
  • 16
    Nilsson CE, Abbas S, Bennemo M, Larsson A, Hamalainen MD, Frostell-Karlsson A. A novel assay for influenza virus quantification using surface plasmon resonance. Vaccine 2010; 28:759766.
  • 17
    Bodle J, Verity EE, Ong C et al. Development of an enzyme-linked immunoassay for the quantitation of influenza haemagglutinin: an alternative method to single radial immunodiffusion. Influenza Other Respir Viruses 2013; 7:191200.
  • 18
    Hashem AM, Gravel C, Farnsworth A et al. A novel synthetic receptor-based immunoassay for influenza vaccine quantification. PLoS ONE 2013; 8:e55428.
  • 19
    Robertson JS, Nicolson C, Harvey R et al. The development of vaccine viruses against pandemic A(H1N1) influenza. Vaccine 2011; 29:18361843.
  • 20
    Schmeisser F, Friedman R, Besho J et al. Neutralizing and protective epitopes of the 2009 pandemic influenza H1N1 hemagglutinin. Influenza Other Respir Viruses 2013; 7:480490.
  • 21
    Schmeisser F, Adamo JE, Blumberg B et al. Production and characterization of mammalian virus-like particles from modified vaccinia virus Ankara vectors expressing influenza H5N1 hemagglutinin and neuraminidase. Vaccine 2012; 30:34133422.
  • 22
    Williams MS, Mayner RE, Daniel NJ et al. New developments in the measurement of the hemagglutinin content of influenza virus vaccines by single-radial-immunodiffusion. J Biol Stand 1980; 8:289296.
  • 23
    Vodeiko GM, Weir JP. Determination of H5N1 vaccine potency using reference antisera from heterologous strains of influenza. Influenza Other Respir Viruses 2012; 6:176187.
  • 24
    Schmeisser F, Vodeiko GM, Lugovtsev VY, Stout RR, Weir JP. An alternative method for preparation of pandemic influenza strain-specific antibody for vaccine potency determination. Vaccine 2010; 28:24422449.
  • 25
    Reno PW, Hoffmann EM. Enhancement of hemagglutination inhibition by complement. Infect Immun 1972; 6:945951.
  • 26
    Feng JQ, Mozdzanowska K, Gerhard W. Complement component C1q enhances the biological activity of influenza virus hemagglutinin-specific antibodies depending on their fine antigen specificity and heavy-chain isotype. J Virol 2002; 76:13691378.
  • 27
    Gerdil C. The annual production cycle for influenza vaccine. Vaccine 2003; 21:17761779.
  • 28
    van de Donk HJ, de Jong JC, van Olderen MF, Osterhaus AD. Monoclonal antibodies for the control of influenza virus vaccines. Dev Biol Stand 1984; 57:251255.